BuXiang Pharmaceutical: Expected to achieve a profit of 320 million to 468 million in 2025, turning losses into profits year-on-year.

Boqiang Pharmaceutical announced on January 27th that it is expected to achieve a net profit attributable to the owners of the parent company of 320 million to 468 million yuan by 2025, turning loss into profit. The company had a loss of 554 million yuan in the same period last year. The main reasons for the expected profit are a decrease in impairment provision for goodwill compared to the same period last year, an increase in drug sales, a decrease in production costs of main products, and a decrease in amortization of evaluation appreciation corresponding to the acquisition of Tonghua Guhong Pharmaceutical Co., Ltd. and Jilin Tiancheng Pharmaceutical Co., Ltd. until the end of 2024.